{"id":"ofatumumab","safety":{"commonSideEffects":[{"rate":"15–20","effect":"Infusion reactions"},{"rate":"20–25","effect":"Upper respiratory tract infections"},{"rate":"10–15","effect":"Headache"},{"rate":"10–15","effect":"Nasopharyngitis"},{"rate":"5–10","effect":"Fatigue"},{"rate":"2–5","effect":"Serious infections"}]},"_chembl":null,"allNames":"kesimpta","_dailymed":{"setId":"77785ce3-e8df-4ca1-8f8e-6c418c6a17de","title":"ARZERRA (OFATUMUMAB) INJECTION, SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ofatumumab targets CD20, a surface antigen expressed on B lymphocytes. By binding to CD20, it triggers B cell destruction through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), thereby reducing the pathogenic B cell population responsible for autoimmune disease. This mechanism reduces relapse rates and disease progression in multiple sclerosis.","oneSentence":"Ofatumumab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduction of autoimmune activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:35:14.666Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease"}]},"trialDetails":[{"nctId":"NCT06444113","phase":"PHASE4","title":"Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-11-25","conditions":"Multiple Sclerosis","enrollment":24},{"nctId":"NCT06733922","phase":"PHASE4","title":"ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-11-27","conditions":"Relapsing Remitting Multiple Sclerosis (RRMS)","enrollment":224},{"nctId":"NCT06869785","phase":"PHASE3","title":"Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-03-13","conditions":"Relapsing Multiple Sclerosis (RMS)","enrollment":196},{"nctId":"NCT02135133","phase":"PHASE2","title":"A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-06","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":27},{"nctId":"NCT05090033","phase":"","title":"Characterizing the Use of Ofatumumab in a Real World Setting","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-12-08","conditions":"Relapsing Multiple Sclerosis","enrollment":103},{"nctId":"NCT03650114","phase":"PHASE3","title":"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-28","conditions":"Relapsing Multiple Sclerosis","enrollment":1882},{"nctId":"NCT06551519","phase":"","title":"A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-28","conditions":"Multiple Sclerosis","enrollment":700},{"nctId":"NCT05344469","phase":"","title":"A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-10","conditions":"Relapsing Multiple Sclerosis","enrollment":800},{"nctId":"NCT06345157","phase":"","title":"ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-30","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":379},{"nctId":"NCT04788615","phase":"PHASE3","title":"Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-23","conditions":"Multiple Sclerosis","enrollment":185},{"nctId":"NCT05084638","phase":"PHASE4","title":"Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-01-25","conditions":"Relapse Remitting Multiple Sclerosis","enrollment":180},{"nctId":"NCT04926818","phase":"PHASE3","title":"Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-05","conditions":"Multiple Sclerosis (MS)","enrollment":129},{"nctId":"NCT03136146","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-09","conditions":"Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia","enrollment":42},{"nctId":"NCT06157086","phase":"","title":"Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-12-21","conditions":"Multiple Sclerosis (MS)","enrollment":302},{"nctId":"NCT05504694","phase":"PHASE1, PHASE2","title":"Ofatumumab in AQP4-IgG Seropositive NMOSD","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2022-06-28","conditions":"Neuromyelitis Optica Spectrum Disorder","enrollment":5},{"nctId":"NCT05090371","phase":"PHASE4","title":"A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-03-02","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":136},{"nctId":"NCT04510220","phase":"PHASE3","title":"9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-09-21","conditions":"Relapsing Multiple Sclerosis","enrollment":10},{"nctId":"NCT07353216","phase":"","title":"Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels","status":"RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2023-12-01","conditions":"Multiple Sclerosis","enrollment":80},{"nctId":"NCT05285904","phase":"","title":"Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-12","conditions":"Multiple Sclerosis","enrollment":107},{"nctId":"NCT05199571","phase":"PHASE4","title":"Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-07-22","conditions":"Relapsing Multiple Sclerosis","enrollment":99},{"nctId":"NCT04486716","phase":"PHASE3","title":"A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-10-19","conditions":"Relapsing Multiple Sclerosis","enrollment":111},{"nctId":"NCT05162638","phase":"NA","title":"Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation","status":"ENROLLING_BY_INVITATION","sponsor":"University of Pennsylvania","startDate":"2022-04-19","conditions":"Multiple Sclerosis, Healthy","enrollment":24},{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":156},{"nctId":"NCT05776888","phase":"","title":"Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-07-10","conditions":"Relapsing Multiple Sclerosis","enrollment":106},{"nctId":"NCT06251986","phase":"","title":"A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-26","conditions":"Relapsing Forms of Multiple Sclerosis","enrollment":310},{"nctId":"NCT06486779","phase":"","title":"Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-12-10","conditions":"Relapsing Multiple Sclerosis (RMS)","enrollment":160},{"nctId":"NCT01496976","phase":"PHASE2","title":"Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2012-03-30","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":45},{"nctId":"NCT04940065","phase":"","title":"Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-30","conditions":"Relapsing-remitting Multiple Sclerosis, Active Secondary Progressive Multiple Sclerosis","enrollment":367},{"nctId":"NCT07149662","phase":"","title":"Immune System Effects in Children Born to Women With Multiple Sclerosis Treated With Monoclonal Antibody Therapy During Pregnancy","status":"NOT_YET_RECRUITING","sponsor":"Region Stockholm","startDate":"2026-02","conditions":"Multiple Sclerosis, Pregnancy","enrollment":111},{"nctId":"NCT01286272","phase":"PHASE2","title":"Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-04-28","conditions":"Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma","enrollment":135},{"nctId":"NCT04353492","phase":"PHASE3","title":"An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-07-14","conditions":"Relapsing Multiple Sclerosis","enrollment":562},{"nctId":"NCT02877303","phase":"PHASE2","title":"Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-11-01","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma","enrollment":80},{"nctId":"NCT05688436","phase":"","title":"A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies","status":"RECRUITING","sponsor":"Biogen","startDate":"2021-09-24","conditions":"Multiple Sclerosis","enrollment":1178},{"nctId":"NCT03500328","phase":"NA","title":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-05-02","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":900},{"nctId":"NCT01258933","phase":"PHASE2","title":"Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-07-06","conditions":"Leukemia, Lymphoma","enrollment":4},{"nctId":"NCT07189325","phase":"PHASE3","title":"A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2025-09","conditions":"Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy","enrollment":250},{"nctId":"NCT06668324","phase":"","title":"Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-11-15","conditions":"Multiple Sclerosis","enrollment":134},{"nctId":"NCT06529406","phase":"PHASE4","title":"Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-07-29","conditions":"Relapsing Multiple Sclerosis","enrollment":100},{"nctId":"NCT05962177","phase":"NA","title":"Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and Serologic","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2023-09-11","conditions":"Multiple Sclerosis","enrollment":400},{"nctId":"NCT06885957","phase":"","title":"Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-07-01","conditions":"NMO Spectrum Disorder","enrollment":200},{"nctId":"NCT03535298","phase":"PHASE4","title":"Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2019-01-03","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":800},{"nctId":"NCT05566756","phase":"","title":"Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-10-28","conditions":"Multiple Sclerosis","enrollment":307},{"nctId":"NCT06867991","phase":"PHASE3","title":"Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis","status":"RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2024-11-08","conditions":"Anti-N-Methyl-D-Aspartate Receptor Encephalitis","enrollment":200},{"nctId":"NCT06121349","phase":"","title":"WOE of Anti-CD20 Therapies","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-12-04","conditions":"Multiple Sclerosis","enrollment":157},{"nctId":"NCT05266469","phase":"","title":"Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-07-26","conditions":"Relapsing Multiple Sclerosis","enrollment":168},{"nctId":"NCT06167642","phase":"","title":"Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab","status":"ENROLLING_BY_INVITATION","sponsor":"Johns Hopkins University","startDate":"2023-05-22","conditions":"Multiple Sclerosis, Tomography, Optical Coherence, Retinal Degeneration","enrollment":75},{"nctId":"NCT01361711","phase":"PHASE2","title":"Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2011-06","conditions":"Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia","enrollment":53},{"nctId":"NCT04878211","phase":"PHASE4","title":"A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-10","conditions":"Relapsing Multiple Sclerosis (RMS)","enrollment":24},{"nctId":"NCT04869358","phase":"PHASE4","title":"Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-05-27","conditions":"Relapsing Multiple Sclerosis","enrollment":34},{"nctId":"NCT01458366","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2011-11-09","conditions":"Non-Hodgkin's Lymphoma","enrollment":38},{"nctId":"NCT01352312","phase":"PHASE1","title":"Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2011-05-25","conditions":"Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin's Lymphoma","enrollment":10},{"nctId":"NCT05171972","phase":"","title":"Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2022-01-29","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":40},{"nctId":"NCT06897657","phase":"","title":"A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-11-06","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":155},{"nctId":"NCT06854341","phase":"","title":"A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-09","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":5448},{"nctId":"NCT06760624","phase":"","title":"Effectiveness of Ofatumumab in Real-world Practice","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-24","conditions":"Multiple Sclerosis","enrollment":779},{"nctId":"NCT01437709","phase":"PHASE2","title":"Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-09","conditions":"Mantle Cell Lymphoma","enrollment":30},{"nctId":"NCT02388048","phase":"PHASE2","title":"Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2015-10","conditions":"Leukemia, Lymphoblastic, Chronic","enrollment":19},{"nctId":"NCT05634967","phase":"","title":"Kesimpta (Ofatumumab) Pregnancy Registry","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-01-05","conditions":"Multiple Sclerosis, Pregnancy","enrollment":725},{"nctId":"NCT05809986","phase":"","title":"Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-11-27","conditions":"Relapsing Multiple Sclerosis","enrollment":174},{"nctId":"NCT06127095","phase":"","title":"A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments","status":"COMPLETED","sponsor":"Biogen","startDate":"2023-11-24","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":474},{"nctId":"NCT06737419","phase":"","title":"Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-09","conditions":"Multiple Sclerosis","enrollment":175},{"nctId":"NCT06711354","phase":"","title":"B-cell Depletion in Offspring to Women With MS Under Immunomodulatory Treatment","status":"NOT_YET_RECRUITING","sponsor":"Region Stockholm","startDate":"2025-06","conditions":"Multiple Sclerosis, B-Cell Deficiency, Offspring, Adult","enrollment":111},{"nctId":"NCT05712369","phase":"NA","title":"B Cells in Idiopathic Nephrotic Syndrome","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2019-04-02","conditions":"Nephrotic Syndrome","enrollment":21},{"nctId":"NCT06654817","phase":"","title":"Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids in the Treatment of Pemphigus Vulgaris","status":"COMPLETED","sponsor":"Chao Ji","startDate":"2023-01-01","conditions":"Pemphigus, Pemphigus Vulgaris (PV)","enrollment":38},{"nctId":"NCT06644638","phase":"","title":"Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Novartis","startDate":"2023-02-15","conditions":"Multiple Sclerosis","enrollment":3632},{"nctId":"NCT04667117","phase":"PHASE4","title":"A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-01-14","conditions":"Relapsing Multiple Sclerosis","enrollment":63},{"nctId":"NCT01243190","phase":"PHASE2","title":"Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-03","conditions":"Chronic Lymphocytic Leukemia","enrollment":44},{"nctId":"NCT06156683","phase":"","title":"Kesimpta Pregnancy and Infant Safety Study Using Real World Data","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-06-30","conditions":"Multiple Sclerosis","enrollment":1500},{"nctId":"NCT03488225","phase":"PHASE2","title":"Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-03-28","conditions":"Acute Lymphoblastic Leukemia in Remission, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":4},{"nctId":"NCT06460324","phase":"","title":"A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-20","conditions":"Multiple Sclerosis","enrollment":38},{"nctId":"NCT02199184","phase":"PHASE2","title":"Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-01-14","conditions":"AIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","enrollment":14},{"nctId":"NCT05334472","phase":"","title":"A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-24","conditions":"Multiple Sclerosis","enrollment":105},{"nctId":"NCT06267781","phase":"","title":"RRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line Therapies","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2022-09-02","conditions":"Multiple Sclerosis","enrollment":30},{"nctId":"NCT01527149","phase":"PHASE2","title":"Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2011-12-06","conditions":"Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma","enrollment":37},{"nctId":"NCT05060354","phase":"","title":"COVID-19 Vaccine Response in Treated MS Patients","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-06-01","conditions":"Multiple Sclerosis, Healthy","enrollment":159},{"nctId":"NCT06159712","phase":"NA","title":"Comparative Study of High-Efficacy Disease Modifying Treatment of Relapsing Multiple Sclerosis","status":"UNKNOWN","sponsor":"University of Aarhus","startDate":"2023-11-27","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":200},{"nctId":"NCT01145209","phase":"PHASE2","title":"Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2010-07-01","conditions":"Small Lymphocytic Lymphoma, CLL (Chronic Lymphocytic Leukemia)","enrollment":32},{"nctId":"NCT04189588","phase":"PHASE2","title":"Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine","status":"COMPLETED","sponsor":"TerSera Therapeutics LLC","startDate":"2020-03-25","conditions":"Oncology Patients Receiving Chemotherapy","enrollment":34},{"nctId":"NCT01060384","phase":"PHASE1, PHASE2","title":"Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2010-03-29","conditions":"Non-Hodgkin's Lymphoma","enrollment":46},{"nctId":"NCT02004522","phase":"PHASE3","title":"A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)","status":"COMPLETED","sponsor":"SecuraBio","startDate":"2013-11","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":319},{"nctId":"NCT02049515","phase":"PHASE3","title":"A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07","status":"COMPLETED","sponsor":"SecuraBio","startDate":"2013-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":99},{"nctId":"NCT01465334","phase":"PHASE2","title":"Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2011-12","conditions":"CLL, SLL","enrollment":30},{"nctId":"NCT05950308","phase":"","title":"Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-01-05","conditions":"Multiple Sclerosis","enrollment":61},{"nctId":"NCT05627271","phase":"","title":"The 'Wearing Off' Effect of DMT","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-01-10","conditions":"Multiple Sclerosis","enrollment":39},{"nctId":"NCT05762003","phase":"","title":"Czech Pharmaco-epidemiological Study on Disease Modifying Drugs","status":"COMPLETED","sponsor":"IMPULS Endowment Fund","startDate":"2019-01-01","conditions":"Multiple Sclerosis","enrollment":17478},{"nctId":"NCT01768338","phase":"PHASE1","title":"Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma","status":"COMPLETED","sponsor":"Michael John Robertson","startDate":"2013-02","conditions":"Non-Hodgkin's Lymphoma","enrollment":9},{"nctId":"NCT04847596","phase":"","title":"A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-05-21","conditions":"Relapsing Multiple Sclerosis","enrollment":25},{"nctId":"NCT05528666","phase":"","title":"Risk Perception in Multiple Sclerosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-09-09","conditions":"Multiple Sclerosis","enrollment":4361},{"nctId":"NCT05576779","phase":"","title":"Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-12-03","conditions":"Multiple Sclerosis","enrollment":2101},{"nctId":"NCT04676555","phase":"","title":"Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-05-11","conditions":"Relapsing Forms of Multiple Sclerosis","enrollment":2},{"nctId":"NCT05414487","phase":"","title":"Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases","status":"UNKNOWN","sponsor":"Tianjin Medical University General Hospital","startDate":"2022-10-15","conditions":"Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Demyelinating Diseases of the Central Nervous System","enrollment":34},{"nctId":"NCT01680965","phase":"PHASE1, PHASE2","title":"Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2012-11-14","conditions":"Chronic Graft Versus Host Disease","enrollment":44},{"nctId":"NCT03280160","phase":"PHASE2","title":"Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2017-09-07","conditions":"Chronic Lymphocytic Leukemia","enrollment":84},{"nctId":"NCT01555541","phase":"PHASE2","title":"Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"C. Babis Andreadis","startDate":"2012-05-25","conditions":"Diffuse Large Cell Lymphoma Relapsed/Refractory","enrollment":19},{"nctId":"NCT02710643","phase":"PHASE2","title":"\"MIRO\" Molecularly Oriented Immuno-radio-therapy","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2014-10","conditions":"Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, Follicular Lymphoma Grade 3A","enrollment":110},{"nctId":"NCT01455051","phase":"PHASE2","title":"Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"Grupo Espanol de trasplantes hematopoyeticos y terapia celular","startDate":"2011-10","conditions":"Chronic Lymphocytic Leukemia","enrollment":25},{"nctId":"NCT03249714","phase":"PHASE2","title":"Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-03-15","conditions":"Relapsing Multiple Sclerosis","enrollment":64},{"nctId":"NCT01481272","phase":"PHASE2","title":"Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients","status":"COMPLETED","sponsor":"Polish Lymphoma Research Group","startDate":"2011-11","conditions":"Diffuse Large B Cell Lymphoma","enrollment":77},{"nctId":"NCT02792231","phase":"PHASE3","title":"Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-08-26","conditions":"Relapsing Multiple Scelrosis","enrollment":955},{"nctId":"NCT03560739","phase":"PHASE2","title":"A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-09-11","conditions":"Multiple Sclerosis","enrollment":284}],"_emaApprovals":[{"name":"Kesimpta","status":"Authorised","regulator":"EMA"}],"_faersSignals":[{"count":5254,"reaction":"FATIGUE"},{"count":4429,"reaction":"HEADACHE"},{"count":3421,"reaction":"PAIN"},{"count":3364,"reaction":"CHILLS"},{"count":3231,"reaction":"PYREXIA"},{"count":2751,"reaction":"INFLUENZA LIKE ILLNESS"},{"count":1683,"reaction":"NAUSEA"},{"count":1572,"reaction":"MULTIPLE SCLEROSIS RELAPSE"},{"count":1450,"reaction":"COVID-19"},{"count":1394,"reaction":"ASTHENIA"}],"_approvalHistory":[{"date":"20240119","type":"SUPPL","sponsor":"NOVARTIS","applicationNumber":"BLA125326"},{"date":"20200820","type":"SUPPL","sponsor":"NOVARTIS","applicationNumber":"BLA125326"},{"date":"20160119","type":"SUPPL","sponsor":"NOVARTIS","applicationNumber":"BLA125326"},{"date":"20091026","type":"ORIG","sponsor":"NOVARTIS","applicationNumber":"BLA125326"},{"date":"20140417","type":"SUPPL","sponsor":"NOVARTIS","applicationNumber":"BLA125326"},{"date":"20240412","type":"SUPPL","sponsor":"NOVARTIS","applicationNumber":"BLA125326"},{"date":"20110920","type":"SUPPL","sponsor":"NOVARTIS","applicationNumber":"BLA125326"},{"date":"20250818","type":"SUPPL","sponsor":"NOVARTIS","applicationNumber":"BLA125326"},{"date":"20220902","type":"SUPPL","sponsor":"NOVARTIS","applicationNumber":"BLA125326"},{"date":"20130924","type":"SUPPL","sponsor":"NOVARTIS","applicationNumber":"BLA125326"},{"date":"20100923","type":"SUPPL","sponsor":"NOVARTIS","applicationNumber":"BLA125326"},{"date":"20160830","type":"SUPPL","sponsor":"NOVARTIS","applicationNumber":"BLA125326"}],"publicationCount":965,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"approved","brandName":"Kesimpta","genericName":"OFATUMUMAB","companyName":"Novartis","companyId":"novartis","modality":"Monoclonal antibody","firstApprovalDate":"2009","aiSummary":"Ofatumumab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduction of autoimmune activity. Used for Relapsing multiple sclerosis (RMS), Chronic lymphocytic leukemia (CLL).","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":"EMEA/H/C/005410"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Kesimpta","application_number":null}],"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}